Abstract
Mahmoud et al.: Matrix Metalloproteinase-10 Overexpression in Urinary Bladder Cancer Matrix metalloproteinase-10 is an extracellular matrix degradation enzyme that facilitates cell invasion in many cancers and is associated with poor clinical outcomes. In urinary bladder cancer, the clinical importance of matrix metalloproteinase-10 remains inadequately explored and poorly related to the patients clinicopathological factors and survival status. Hence, this study was conducted to explore matrix metalloproteinase-10 prognostic value in bladder cancer using a cohort of patients in Saudi Arabia. A total of 170 primary transitional cell carcinoma tissue sections of consent patients were prepared and arranged as tissue microarray, and the expression of matrix metalloproteinase-10 was analysed by immunohistochemistry. The potential clinical value of matrix metalloproteinase-10 was assessed by a correlation analysis of its expression with the patient's clinicopathological features. The present data revealed that moderate (+2) and high (+3) matrix metalloproteinase-10 expression was detected in 47 % of our bladder cancer patient's cohort. The expression was strongly associated with low-grade non-invasive tumours. The analysis also displayed a significant positive association of matrix metalloproteinase-10 expression with better overall survival and a low recurrence rate (p=0.023). The study showed an association of matrix metalloproteinase-10 expression with less invasive tumorigenic profiles and a better overall survival rate. This finding may suggest matrix metalloproteinase-10 as a biomarker for favourable treatment response. Further prospective investigations are needed to profoundly evaluate matrix metalloproteinase-10 functional role in bladder cancer.